Ophthotech meets $50 million enrollment milestone under Novartis agreement

Ophthotech Corporation announced in a press release that it has reached a $50 million enrollment milestone payment from Novartis Pharma. The payment is part of the ex-U.S. licensing and commercialization agreement between the two companies with a common focus on the treatment of wet age-related macular degeneration.